Day One Biopharmaceuticals, Inc. (DAWN) Q2 2021 Earnings Results

Day One Biopharmaceuticals Misses on EPS, Stock Down 3.31%

Day One Biopharmaceuticals reported a significant loss per share, which contributed to a 3.31% decline in stock price. The lack of revenue information and guidance may raise concerns among investors about the company's financial health and future prospects. The focus on ongoing clinical trials suggests that the company is still in a developmental phase, which can be risky for investors.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-5.04	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a commitment to advancing their clinical programs. However, they did not offer specific insights into future performance.

Management did not provide specific guidance for future quarters.

The company is focusing on its ongoing clinical trials and research efforts.

Day One Biopharmaceuticals Misses on EPS, Stock Down 3.31%

Key numbers

Management commentary

Day One Biopharmaceuticals, Inc.

More earnings this week

Day One Biopharmaceuticals Misses on EPS, Stock Down 3.31%

Key numbers

Management commentary